Assessing a Circulating Tumor (ctDNA) and Positron Emission Tomography (PET)-Oriented Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL). A Multicenter, Open-label, Phase II Trial
Latest Information Update: 18 Apr 2024
At a glance
- Drugs Acalabrutinib (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Vincristine (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 12 Apr 2024 Planned primary completion date changed from 1 Mar 2026 to 1 Oct 2025.
- 12 Apr 2023 Planned primary completion date changed from 1 Mar 2025 to 1 Mar 2026.
- 14 May 2021 Status changed from not yet recruiting to recruiting.